Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study

Journal:

The Lancet Oncology

Published:

2025-11-26

DOI:

10.1016/s1470-2045(25)00543-1

Affiliations:

38

Authors:

33

Go to article

Institutions	Authors	Share
Hengrui, China	2.000000	0.06
Fudan University Shanghai Cancer Center (FUSCC), China	1.000000	0.03
The Sixth People's Hospital of Shenyang, China	1.000000	0.03
Republican Clinical Oncology Dispensary of the City of Ufa, Russia	1.000000	0.03
Kharkiv Regional Clinical Oncology Center, Ukraine	1.000000	0.03
The First Affiliated Hospital of Nanchang University, China	1.000000	0.03
Zhongshan Hospital, Fudan University, China	1.000000	0.03
The Second Affiliated Hospital of Chongqing Medical University, CQMU, China	1.000000	0.03
Second Affiliated Hospital, AHMU, China	1.000000	0.03
National Taiwan University Hospital (NTUH), Taiwan	1.000000	0.03
The First Affiliated Hospital, USTC, China	1.000000	0.03
State Key Laboratory of Translational Oncology, CUHK, China	1.000000	0.03
Sun Yat-sen Memorial Hospital, SYSU, China	1.000000	0.03
University Hospital of Verona, Italy	1.000000	0.03
Tongji Hospital (TJH), HUST, China	1.000000	0.03
Peking University International Hospital (PKUIH), China	1.000000	0.03
The University of Texas MD Anderson Cancer Center, United States of America (USA)	1.000000	0.03
Sun Yat-sen University Cancer Center (SYSUCC), SYSU, China	1.000000	0.03
Hunan Cancer Hospital, China	1.000000	0.03
West China School of Medicine/West China Hospital of Sichuan University (WCSM/WCH), SCU, China	1.000000	0.03
The First Hospital of Jilin University, China	1.000000	0.03
State Institution of Healthcare Regional Clinical Oncology Dispensary, Russia	1.000000	0.03
The First Affiliated Hospital of Guangxi Medical University, China	1.000000	0.03
Sir Run Run Shaw Hospital (SRRSH), Zhejiang University School of Medicine, China	1.000000	0.03
Fujian Medical University Union Hospital, China	1.000000	0.03
Harbin Medical University Cancer Hospital, China	1.000000	0.03
Nanfang Hospital, China	1.000000	0.03
Sichuan Cancer Hospital, China	0.500000	0.02
University of Electronic Science and Technology of China (UESTC), China	0.500000	0.02
Provincial Specialist Hospital in Wroclaw, Poland	0.500000	0.02
Centrum Badań Klinicznych, Poland	0.500000	0.02
Princess Margaret Cancer Centre, U of T, Canada	0.333333	0.01
Affiliated Jinling Hospital, NJU, China	0.333333	0.01
Nanjing University of Chinese Medicine (NJUCM), China	0.333333	0.01
Nanjing Medical University (NJMU), China	0.333333	0.01
Toronto General Hospital (TGH), U of T, Canada	0.333333	0.01
Hannover Medical School (MHH), Germany	0.333333	0.01

Interested in Oncology and Carcinogenesis?